[go: up one dir, main page]

WO2002053172A3 - Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover - Google Patents

Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover Download PDF

Info

Publication number
WO2002053172A3
WO2002053172A3 PCT/US2001/049272 US0149272W WO02053172A3 WO 2002053172 A3 WO2002053172 A3 WO 2002053172A3 US 0149272 W US0149272 W US 0149272W WO 02053172 A3 WO02053172 A3 WO 02053172A3
Authority
WO
WIPO (PCT)
Prior art keywords
wounds
rate
peptide substrate
turnover
matrix
Prior art date
Application number
PCT/US2001/049272
Other languages
French (fr)
Other versions
WO2002053172A2 (en
Inventor
Kevin P Mcgrath
Stephen Quirk
Original Assignee
Kimberly Clark Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kimberly Clark Co filed Critical Kimberly Clark Co
Priority to AU2002241664A priority Critical patent/AU2002241664A1/en
Publication of WO2002053172A2 publication Critical patent/WO2002053172A2/en
Publication of WO2002053172A3 publication Critical patent/WO2002053172A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to novel peptides and methods for enhancing wound healing, especially chronic wounds. The peptides of the present invention act as substrates for proteinases found in wounds, such as matrix metalloproteinases (MMPs) and human neutrophil elastase. Tailoring of the peptide sequences proveds control of the healing process. The invention also relates to methods of treating wounds and inhibiting degradation of collagen, elastase, stromelysin, and other proteins dound in wounds.
PCT/US2001/049272 2000-12-29 2001-12-21 Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover WO2002053172A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002241664A AU2002241664A1 (en) 2000-12-29 2001-12-21 Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75307800A 2000-12-29 2000-12-29
US09/753,078 2000-12-29

Publications (2)

Publication Number Publication Date
WO2002053172A2 WO2002053172A2 (en) 2002-07-11
WO2002053172A3 true WO2002053172A3 (en) 2004-02-26

Family

ID=25029062

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/049272 WO2002053172A2 (en) 2000-12-29 2001-12-21 Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover

Country Status (2)

Country Link
AU (1) AU2002241664A1 (en)
WO (1) WO2002053172A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030712A1 (en) * 2002-10-01 2004-04-15 Johnson & Johnson Medical Limited Controlled release therapeutic wound dressings
DE102005007468A1 (en) * 2005-02-16 2006-08-31 Beiersdorf Ag Covalently bound active complexes, from which stress-activatable skin enzymes release an active substance

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2131813A (en) * 1982-12-16 1984-06-27 Monsanto Co Peptide substrates for mammalian collagenase
EP0126009A1 (en) * 1983-05-16 1984-11-21 Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) Peptide derivatives, their preparation and use as elastase inhibitors
US5534496A (en) * 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5612194A (en) * 1989-06-23 1997-03-18 Trustees Of The University Of Pennsylvania Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
US5618790A (en) * 1990-10-05 1997-04-08 Queen's University At Kingston Protease mediated drug delivery system
WO2000063233A2 (en) * 1999-04-21 2000-10-26 University Of Florida Research Foundation, Inc. Peptides and the use thereof to control pests
WO2001046220A2 (en) * 1999-12-22 2001-06-28 Polymun Scientific Immunbiologische Forschung Gmbh Bioactive oligopeptides
WO2002038108A2 (en) * 2000-11-03 2002-05-16 The J. David Gladstone Institutes Methods of treating disorders related to apoe

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2131813A (en) * 1982-12-16 1984-06-27 Monsanto Co Peptide substrates for mammalian collagenase
EP0126009A1 (en) * 1983-05-16 1984-11-21 Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) Peptide derivatives, their preparation and use as elastase inhibitors
US5612194A (en) * 1989-06-23 1997-03-18 Trustees Of The University Of Pennsylvania Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
US5618790A (en) * 1990-10-05 1997-04-08 Queen's University At Kingston Protease mediated drug delivery system
US5534496A (en) * 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
WO2000063233A2 (en) * 1999-04-21 2000-10-26 University Of Florida Research Foundation, Inc. Peptides and the use thereof to control pests
WO2001046220A2 (en) * 1999-12-22 2001-06-28 Polymun Scientific Immunbiologische Forschung Gmbh Bioactive oligopeptides
WO2002038108A2 (en) * 2000-11-03 2002-05-16 The J. David Gladstone Institutes Methods of treating disorders related to apoe

Also Published As

Publication number Publication date
WO2002053172A2 (en) 2002-07-11
AU2002241664A1 (en) 2002-07-16

Similar Documents

Publication Publication Date Title
WO2003018748A3 (en) Anti-cancer and wound healing compounds
ATE323157T1 (en) PROTEASE FOR ACTIVATION OF CLOTTING FACTOR VII
ATE532858T1 (en) HUMAN CLOTTING FACTOR VII POLYPEPTIDES
HUP9902698A2 (en) Human bikunin
TR200101903T2 (en) New malonic acid derivatives, their preparation processes.
WO1996035788A3 (en) Kunitz type protease inhibitors
WO2003066842A3 (en) Method for producing recombinant proteins in micro-organisms
WO2003008443A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
HRP20090003T3 (en) Oligopeptides for reducing elevated blood urea concentration
AU4166102A (en) Multifunctional protease inhibitors and their use in treatment of disease
WO2002053172A3 (en) Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover
WO1999063090A3 (en) Protease inhibitor peptides
EP1497326A4 (en) PROTHROMBIN ACTIVATING PROTEIN
YU76403A (en) Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis
WO2003053999A3 (en) Selective arylguanidine peptides as urokinase inhibitors
Potempa et al. The primary elastase inhibitor (elastasin) and trypsin inhibitor (contrapsin) in the goat are serpins related to human α 1-anti-chymotrypsin
Dufour et al. Limited proteolysis of β-lactoglobulin using thermolysin. Effects of calcium on the outcome of proteolysis
WO2004106519A3 (en) Mrp8/mrp14 inhibitors and the use thereof for preventing and/or treating hypertrophic scars and keloids
WO2003016273A3 (en) Peptide arginals and methods for treating disseminated intravascular coagulation
DE60128084D1 (en) USE OF INACTIVE CLN2 PROENZYM FOR THE TREATMENT OF LINCL
WO2003036264A3 (en) Treating diseases mediated by metalloprotease-shed proteins
Lombard et al. Proteinase 3 hydrolysis of peptides derived from human elastin exon 24
KR100390655B1 (en) Halyxin, Blood Anticoagulant Protein Derived from Snake Venom
Ávila et al. Neuwiedase (Bothrops neuwiedi)
Tschesche et al. Function and structure of human leucocyte collagenase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP